Stocks

Motilal Oswal initiates Molbio Diagnostics coverage with Buy rating

6 October 2026Source: Economic Times 1 min read

Quick Summary

Motilal Oswal has initiated coverage on Molbio Diagnostics, assigning a Buy rating. The brokerage set a target of ₹1,800, indicating a potential upside of 21%. This assessment is based on the strong growth potential in decentralized molecular diagnostics.

Key Takeaways

Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating.
The target price is ₹1,800.
This implies a 21% upside potential.
Molbio's Truenat platform operates 12,500+ devices globally.

Why It Matters

Brokerage reports can provide investors with an analytical perspective on a company's potential. Such initiations of coverage often bring a stock into broader market attention and offer insights into its perceived valuation and growth prospects.

The IPO in numbers

Molbio Diagnostics Limited's IPO is a 100% Book Building issue with an issue size of ₹939.7 crore. The price band is set at ₹768 to ₹807 per equity share, with a lot size of 18 shares, meaning one lot would cost ₹14,526 at the upper price band. Bidding is scheduled from August 10, 2026, to August 12, 2026.

Figures from CAPITA1's own IPO record, not from the news report.

The headline, summary, takeaways and analysis on this page are written by CAPITA1's AI from the source report. For educational purposes only. Not investment advice.

The IPO in this story

Molbio Diagnostics Limited

ListedMainboard

Price Band: ₹768 – ₹807
GMP: ₹130 (+16.11%)
Subscription: —

Opens 10 Aug 2026 · Closes 12 Aug 2026

CAPITA1 desk — unofficial grey-market estimate — Unofficial grey-market estimate — not an exchange price. Updated 11 Aug 2026, 08:47 am.

View Full IPO Details